virus (VSV), and use this information to design more effective, safer recombinant live virus vaccines against Yersinia pestis and pox viruses. Previous strategies for attenuating pathogenesis of recombinant VSV vaccine vectors have focused on reducing the ability of the virus to produce infectious progeny. This has the I The goal of this project is to identify the mechanisms that account for pathogenesls of vesicular stomatitis undesired effect of reducing the level of antigen expression and reducing the subsequent immune response. In contrast, we have developed a new strategy for attenuating viral pathogenesis by reducing the ability of the virus to suppress host innate immune responses without compromising the yield of infectious progeny or the level of antigen expression from infected cells.These vectors are designed to have greater efficacy by enhancing innate immune mechanisms and greater safety by modifying the determinants of viral pathogenesis.
Aim 1 is to determine the pathogenesis and cytokine production by VSV vectors that activate innate immune mechanisms. These experiments involve analysis of virus dissemination and cytokine production in mice infected with recombinant M protein mutant viruses, which fail to suppress host innate immune responses, and recombinant viruses that express Salmonella flagellin as an activator of toll-like receptors responsible for induction of innate immune responses.
Aim 2 is to test the hypothesis that activation of innate immune mechanisms by mutant viruses leads to more effective adaptive immune responses. The ability of recombinant mutant VSV vectors to elicit antibodies against a bacterial pathogen and to protect against bacterial challenge will be tested using vectors that express the F1 and V antigens of Y. pestis. The ability of these vectors to elicit cytotoxic T lymphocytes and protect against respiratory challenge with poxviruses will be tested using vectors that express surrogate antigens expressed by recombinant vaccinia viruses. These experiments address directly the dilemma faced in developing attenuated viruses as vaccines: a virus that is too attenuated for growth will not elicit a very effective immune response, while one that is not attenuated enough will be unsafe. In contrast, a virus that is attenuated by being unable to suppress the host response may be a more effective and safer vaccine.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI060642-04
Application #
7447879
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
4
Fiscal Year
2007
Total Cost
$250,652
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Beauchamp, Nicole M; Yammani, Rama D; Alexander-Miller, Martha A (2012) CD8 marks a subpopulation of lung-derived dendritic cells with differential responsiveness to viral infection and toll-like receptor stimulation. J Virol 86:10640-50
Clark, Kimberly M; Johnson, John B; Kock, Nancy D et al. (2011) Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge. Virology 419:97-106
Bates, John T; Graff, Aaron H; Phipps, James P et al. (2011) Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88. J Immunol 186:6255-62
Ahmed, Maryam; Puckett, Shelby; Arimilli, Subhashini et al. (2010) Stimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin. J Virol 84:12093-8
Manuse, Mary J; Briggs, Caitlin M; Parks, Griffith D (2010) Replication-independent activation of human plasmacytoid dendritic cells by the paramyxovirus SV5 Requires TLR7 and autophagy pathways. Virology 405:383-9
Beauchamp, Nicole M; Busick, Rhea Y; Alexander-Miller, Martha A (2010) Functional divergence among CD103+ dendritic cell subpopulations following pulmonary poxvirus infection. J Virol 84:10191-9
Braxton, Cassandra L; Puckett, Shelby H; Mizel, Steven B et al. (2010) Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J Virol 84:3552-61
Mizel, Steven B; Bates, John T (2010) Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 185:5677-82
Delaney, Kristen N; Phipps, James P; Johnson, John B et al. (2010) A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol 23:201-10
Palmer, Ellen M; Holbrook, Beth C; Arimilli, Subhashini et al. (2010) IFNgamma-producing, virus-specific CD8+ effector cells acquire the ability to produce IL-10 as a result of entry into the infected lung environment. Virology 404:225-30

Showing the most recent 10 out of 25 publications